Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 3;29(4):445-453.
doi: 10.5603/rpor.101528. eCollection 2024.

Stereotactic ablative radiotherapy (SABR) for pelvic nodal oligorecurrence in prostate cancer

Marta Lopez-Valcarcel  1 , Francisco J Valcarcel  1 , Joaquin Velasco  1 , Irma Zapata  1 , Ruth Rodriguez  2 , Jorge Cardona  3 , Beatriz Gil  1 , Sofia Cordoba  1 , Raquel Benlloch  1 , Maria Hernandez  1 , Sofia Santana  1 , Ricardo Gomez  1 , Cristina De la Fuente  1 , M Isabel Garcia-Berrocal  1 , Carlos Regueiro  1 , Jesus Romero  1
Affiliations

Stereotactic ablative radiotherapy (SABR) for pelvic nodal oligorecurrence in prostate cancer

Marta Lopez-Valcarcel et al. Rep Pract Oncol Radiother. .

Abstract

Background: This study evaluated the clinical outcomes of stereotactic ablative radiotherapy (SABR) in the treatment of oligometastatic pelvic node prostate cancer to delay androgen deprivation therapy (ADT).

Materials and methods: Pelvic lymph node metastases were identified by 11C-choline positron emission tomography (PET)-computed tomography (CT), and patients were not receiving ADT. SABR was administered using linear accelerators with intensity-modulated and image-guided radiotherapy, at a prescribed dose of 35 Gy in 5 fractions over 2 weeks. Response was assessed using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria, and prostate-specific antigen (PSA) levels were monitored post-SABR. Toxicity and quality of life were assessed by the Common Terminology Criteria for Adverse Events Toxicity (CTCAE) v.5.0 and European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaires QLQ-C30/QLQ-PR25, respectively. Kaplan-Meier and T-test were used for statistical analysis.

Results: Between June 2015 and November 2023, 56 patients with 85 lesions were treated at our institution. Median follow-up was 30 months [95% confidence interval (CI): 24-33.6]. Prostatectomy was the radical treatment in 85.7% of patients, and radiotherapy in 14.3%. Response rates were 67.1% for complete response, 27.4% for partial response, and 1.4% for stable disease. In-field progression was observed in only 3 lesions (3.5%). The median time to biochemical relapse post-SABR was 15 months (95% CI: 11.4-18.6). Three-year pelvic nodal and distant progression-free survival were 62.5% and 80%, respectively. There was a significant decrease in PSA levels after SABR compared to pretreatment levels (0.77 vs. 2.16 ng/mL respectively, p = 0.001). No grade ≥ 2 genitourinary or gastrointestinal toxicities. The median global health status score was 83.33 points at both time points analysed.

Conclusion: SABR can delay the ADT and provide excellent local control while preserving quality of life.

Keywords: oligometastases; oligorecurrence; pelvic lymph nodes; prostate cancer; stereotactic ablative radiotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
Distribution pelvic lymph nodes oligometastases. CI — common iliac; EI — external iiac; II — internal iliac;
Figure 2
Figure 2
Local relapse progression-free survival and new treatment-free survival Kaplan Meier curves
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763. - DOI - PubMed
    1. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–974. doi: 10.1016/j.ijrobp.2006.04.029. - DOI - PubMed
    1. Shore ND, Moul JW, Pienta KJ, et al. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2024;27(2):192–201. doi: 10.1038/s41391-023-00712-z. - DOI - PMC - PubMed
    1. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–382. doi: 10.1038/nrclinonc.2011.44. - DOI - PubMed
    1. Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–e28. doi: 10.1016/S1470-2045(19)30718-1. - DOI - PubMed

LinkOut - more resources